BRPI0711256A2 - composições anticancerìgenas e método de tratamento de cáncer - Google Patents

composições anticancerìgenas e método de tratamento de cáncer Download PDF

Info

Publication number
BRPI0711256A2
BRPI0711256A2 BRPI0711256-4A BRPI0711256A BRPI0711256A2 BR PI0711256 A2 BRPI0711256 A2 BR PI0711256A2 BR PI0711256 A BRPI0711256 A BR PI0711256A BR PI0711256 A2 BRPI0711256 A2 BR PI0711256A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
taxane
anticancer
produce
compositions
Prior art date
Application number
BRPI0711256-4A
Other languages
English (en)
Inventor
Richard D Olson
Gerald M Walsh
Original Assignee
Gem Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gem Pharmaceuticals Llc filed Critical Gem Pharmaceuticals Llc
Publication of BRPI0711256A2 publication Critical patent/BRPI0711256A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES ANTICANCERìGENAS E MéTODO DE TRATAMENTO DE CáNCER. Uma 13-deoxi antraciclina e uma taxana podem ser administradas a um paciente simultanea, separada, sequencial ou consecutivamente para produzir um efeito anticâncer terapêutico com toxicidade e perfil de efeito colateral reduzido, comparado com a administração de quantidades equiefetivas de um ou outro composto apenas. Também é proporcionada uma composição ou uma preparação de 13-deoxi antraciclinas e uma taxana para produzir um potente efeito terapêutico anticancerígeno.
BRPI0711256-4A 2006-04-21 2007-04-23 composições anticancerìgenas e método de tratamento de cáncer BRPI0711256A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/408,000 US7776832B2 (en) 2006-04-21 2006-04-21 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
PCT/US2007/067225 WO2007124489A2 (en) 2006-04-21 2007-04-23 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Publications (1)

Publication Number Publication Date
BRPI0711256A2 true BRPI0711256A2 (pt) 2011-08-30

Family

ID=38620193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711256-4A BRPI0711256A2 (pt) 2006-04-21 2007-04-23 composições anticancerìgenas e método de tratamento de cáncer

Country Status (21)

Country Link
US (2) US7776832B2 (pt)
EP (1) EP2010191B1 (pt)
JP (1) JP5011377B2 (pt)
KR (1) KR101514336B1 (pt)
CN (1) CN101426509A (pt)
AU (1) AU2007240264B2 (pt)
BR (1) BRPI0711256A2 (pt)
CA (1) CA2649753C (pt)
CO (1) CO6190526A2 (pt)
DK (1) DK2010191T3 (pt)
ES (1) ES2840977T3 (pt)
IL (1) IL194707A (pt)
MX (1) MX2008013546A (pt)
MY (1) MY148571A (pt)
NZ (1) NZ572012A (pt)
PL (1) PL2010191T3 (pt)
PT (1) PT2010191T (pt)
RU (1) RU2421224C2 (pt)
UA (1) UA90597C2 (pt)
WO (1) WO2007124489A2 (pt)
ZA (1) ZA200808892B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008000A (es) * 2009-01-30 2011-09-15 Enanta Pharm Inc Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
EP3967306A1 (en) 2012-10-01 2022-03-16 Mayo Foundation for Medical Education and Research Cancer treatments
KR20210125603A (ko) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN107530283A (zh) * 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) * 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
AU2017321798B2 (en) 2016-09-01 2023-06-15 Mayo Foundation For Medical Education And Research Methods and compositions for targeting T-cell cancers
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
JP2019526587A (ja) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｐｄ−ｌ１を発現する癌を処置する方法
US10450340B2 (en) * 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
AU2018234903B2 (en) 2017-03-16 2024-02-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US5942605A (en) * 1998-03-03 1999-08-24 Gem Pharmaceuticals, Inc. 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US9904704B2 (en) 2014-04-22 2018-02-27 Openx Software Limited System and method for controlling audience data and tracking

Also Published As

Publication number Publication date
JP5011377B2 (ja) 2012-08-29
CA2649753C (en) 2011-09-27
US7776832B2 (en) 2010-08-17
PL2010191T3 (pl) 2021-05-04
CN101426509A (zh) 2009-05-06
JP2009534426A (ja) 2009-09-24
RU2008141682A (ru) 2010-05-27
EP2010191A2 (en) 2009-01-07
CA2649753A1 (en) 2007-11-01
MX2008013546A (es) 2009-01-20
US8158591B2 (en) 2012-04-17
ES2840977T3 (es) 2021-07-07
IL194707A (en) 2015-10-29
WO2007124489A3 (en) 2008-10-23
DK2010191T3 (da) 2020-12-14
AU2007240264B2 (en) 2012-11-01
NZ572012A (en) 2011-09-30
AU2007240264A1 (en) 2007-11-01
EP2010191B1 (en) 2020-10-07
IL194707A0 (en) 2009-08-03
US20100311679A1 (en) 2010-12-09
KR20090010981A (ko) 2009-01-30
EP2010191A4 (en) 2010-05-26
PT2010191T (pt) 2021-01-04
MY148571A (en) 2013-04-30
ZA200808892B (en) 2009-10-28
WO2007124489A2 (en) 2007-11-01
US20070249547A1 (en) 2007-10-25
CO6190526A2 (es) 2010-08-19
UA90597C2 (ru) 2010-05-11
KR101514336B1 (ko) 2015-04-22
RU2421224C2 (ru) 2011-06-20

Similar Documents

Publication Publication Date Title
BRPI0711256A2 (pt) composições anticancerìgenas e método de tratamento de cáncer
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
AR058130A1 (es) Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer
HK1102991A1 (en) Pharmaceutical formulation of decitabine
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
SI2268292T1 (en) Method and compositions for the treatment of cancer
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
TN2012000493A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
BR112012002265B8 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]